Controlled release polymeric ocular delivery of acyclovir

Pharmaceutical Development and Technology

Volumn 15, Issue 4, 2010, Pages 369-378

  Deshpande, Praful Balavant ^a   Dandagi, Panchaxari ^a   Udupa, Nayanabhirama ^b   Gopal, Shavi V ^b   Jain, Samata S ^a   Vasanth, Surenalli G ^b  

^a JAWAHARLAL NEHRU MEDICAL COLLEGE   (India)

^b MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Acyclovir; binary systems; differential scanning calorimetry; ocular insert; cyclodextrin

Indexed keywords

ACICLOVIR; ACIVIR; BETA CYCLODEXTRIN; CELLACEFATE; POLYMER; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; BETA CYCLODEXTRIN DERIVATIVE; CELLULOSE; DELAYED RELEASE FORMULATION; DRUG CARRIER; HYDROXYPROPYLMETHYLCELLULOSE; METHYLCELLULOSE;

ANIMAL EXPERIMENT; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; GAMMA RADIATION; MALE; MOISTURE; NONHUMAN; PHYSICAL CHEMISTRY; PHYSICOCHEMICAL MODEL; PRIORITY JOURNAL; WATER TRANSPORT; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG DELIVERY SYSTEM; RABBIT; SOLUBILITY; TIME; TOPICAL DRUG ADMINISTRATION;

ACYCLOVIR; ADMINISTRATION, TOPICAL; ANIMALS; ANTIVIRAL AGENTS; BETA-CYCLODEXTRINS; CELLULOSE; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRUG STORAGE; GAMMA RAYS; HYPROMELLOSE DERIVATIVES; MALE; METHYLCELLULOSE; POLYMERS; RABBITS; SOLUBILITY; TIME FACTORS;

EID: 77954007435     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450903262017     Document Type: Article

References (25)

1. Sasaki H, Tei C, Nishid K, Nakamura J. Drug release from an ophthalmic insert of a beta-blocker as an ocular delivery system. J Con Rel 1993;27:127-137.
2. Kawakami S, Nishida K, Mukai T, Yamamura K, Nakamura J, Sakaeda T, Nakashima M, Sasaki H. Controlled release and ocular absorption of tilisolol utilizing ophthalmic insert-incorporated lipophilic prodrugs. J Con Rel 2001;76:255-263.
3. Saettone MF. Progress and problems in ophthalmic drug delivery. Business Briefing Pharmatech 2002;2:1-6.
4. Mehanna MM, Elmaradny HA, Samaha MW. Ciprofloxacin liposomes as vesicular reservoirs for ocular delivery: formulation, optimization, and in vitro characterization. Drug Dev Ind Pharm 2008;24:1-11.
5. Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv Drug Deliv Rev 1995;16:95-106.
6. Charoo NA, Kohli KA, Ali A, Anwer A. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: In vitro and in vivo studies. Drug Dev Ind Pharm 2003;29(2):215-221.
7. Hornof M, Weyenberg W, Ludwig A, Bernkop-Schnurch A. Mucoadhesive ocular insert based on thiolated poly (acrylic acid): Development and in vivo evaluation in humans. J Con Rel 2003;89:419-428.
8. Chien YW.Ocular drug delivery systems. In: Chein YW, ed. Novel drug delivery systems. Vol.2. New York: Marcel Decker Inc; 1988:269-301.
9. Rao V, Shyale S. Preparation and evaluation of ocular inserts containing norfloxacin. Turk J Med Sci 2004;34:239-246.
10. Vijaya C, Somanath S, Rajan NSMG, Jayaprakash S, Nagarajan M. Controlled release ocuserts of chloramphenicol-design and evaluation. Eastern Pharm 2001;44(250):105-108.
11. Rossel CVP, Carreno JS, Rodriguez-Baeza M, Alderete JB. Inclusion complex of the antiviral drug acyclovir with cyclodextrin in aqueous solution and its solid phase. Quimica Nova 2000;23(6):749-752.
12. Govindarajan R, Nagarsenker MS. Influence of preparation methodology on solid-state properties of an acidic drug-cyclodextrin system. J Pharm Pharmacol 2004;56:725-733.
13. Zingone G, Rubessa F. Preformulation study of the inclusion complex warfarin-α-cyclodextrin. Int J Pharm 2005;291: 3-10.
14. Chowdary KPR, Rao KRSS, Lakshmi YR. Enhancement of solubility and dissolution rates of Rofecoxib by complexing with α-cyclodextrin. Int J Pharm Excip 2004;3(2):53-56.
15. Ali A, Sharma SN. Fabrication of a through flow apparatus for in vitro determination of drugs from ophthalmic preparations. Indian Drugs 1991;29(4):157-160.
16. Fresta M, Fontana G, Bucolo C, Cavallaro G, Giammona G, Puglisi G. Ocular tolerability and in vivo bioavailability of polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir. J Pharm Sci 2001;90(3):288-297.
17. Martin A, Bustamante PI, Chun AHC. Physical pharmacy. Vol.4. New Delhi: B.I. Waverly Private Ltd; 1994:315.
18. Vijayraghavan C. Practical hand book of physical pharmaceutics. Vol.1. Madras: New Century Book House (P) Ltd; 1995: 30-34.
19. Mortazavi SA, Smart JD. An investigation into the role of water movement and mucus gel dehydration in mucoadhesion. J Con Rel 1993;25:197-203.
20. Sultana Y, Aqil M, Ali A. Ocular inserts for controlled delivery of pefloxacin mesylate: Preparation and evaluation. Acta Pharm 2005;55:305-314.
21. Loukas YL, Yraka V, Gregoriades G. Novel non-acidic formulations of haloperidol complexed with α-cyclodextrin derivatives. J Pharm Biomed Anal 1997;16:263-268.
22. Loftsson T, Fridriksdottir H, Thorisdottir S, Stefansson E. The effect of hydroxypropyl methylcellulose on the release of dexamethasone from aqueous 2-hydroxypropyl-α-cyclodextrin formulations. Int J Pharmacol 1994;104:181-184.
23. Wang S, Dexin L, Yoshima I, Xia L, Jinghai Z, Chunfu W. An ocular drug delivery system containing zinc diethyldithiocarbamate and HPCD inclusion complex-corneal permeability, anticataract effects and mechanism studies. J Pharm Pharmacol 2004;56:1251-1257.
24. Shinde AJ, Garala KC, More HN. Development and characterization of transdermal therapeutics system of tramadol hydrochloride. Asian J Pharm 2008:265-269.
25. Mundada AS, Shrikhande BK. Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert. Curr Eye Res 2008;33:469-475.